Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back

Core Insights - The sale of shares by Aristotle Capital Boston indicates profit-taking in Supernus Pharmaceuticals, which is operationally performing well but facing scrutiny regarding its durability and valuation [1][9]. Company Overview - Supernus Pharmaceuticals is a mid-cap biopharmaceutical company focused on therapies for central nervous system (CNS) disorders, with a market capitalization of $2.7 billion and a revenue of $681.5 million over the trailing twelve months (TTM) [4][5]. - The company reported a net income loss of $19.1 million TTM, indicating challenges in profitability despite operational momentum [4][10]. Recent Developments - Aristotle Capital Boston reduced its holdings in Supernus by 503,122 shares, bringing its total position down to 305,273 shares valued at $14.6 million as of September 30 [2]. - The shares sold were valued at approximately $10.9 million, reflecting a strategic reallocation of capital rather than a loss of confidence in the company [2][11]. Financial Performance - Supernus reported a 9% year-over-year revenue increase in the third quarter, totaling $192.1 million, driven by over 50% growth from its four key products [10]. - The company raised its full-year revenue guidance, indicating confidence in its near-term execution despite facing rising expenses and integration risks [10][11]. Market Position - Supernus shares have increased by approximately 31% over the past year, significantly outperforming the S&P 500, which rose about 13% in the same period [3]. - The company’s focus on specialty conditions and established distribution channels supports its competitive position in the U.S. CNS therapeutics market [5][8].